|
Lorlatinib Clinical Trials
9 actively recruiting trials across 4 locations
▲ +1 trial since August 2026
Also known as: 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-, LOBRENA, Lorbrena, Lorviqua, PF 06463922 +2 more
Pipeline
Early 1: 1Phase 1: 2Phase 2: 3Phase 3: 1
Top Sponsors
- The Netherlands Cancer Institute1
- Sichuan Cancer Hospital and Research Institute1
- Pfizer1
- Nuvectis Pharma, Inc.1
- Nationwide Children's Hospital1
Indications
- Cancer8
- Lung Cancer6
- ALK Positive Non-small Cell Lung Cancer3
- ALK+ Non-Small-Cell Lung Carcinoma2
- ALK Positive1
Other5 trials
Birmingham, Alabama1 trial
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Hospital of Alabama
Phase 3
Aurora, Colorado1 trial
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Children's Hospital Colorado
Early 1
Houston, Texas1 trial
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
The University of Texas M. D. Anderson Cancer Center
Phase 2
Fairfax, Virginia1 trial
Study of NXP900 With Lorlatinib in ALK+ Lung Cancer
NEXT Virginia
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.